Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Neoplasms
Interventions: Fitbit Charge HR®; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions: parsaclisinib, placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Whittier, California • Miami, Florida + 6 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 40
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more

Conditions: Pregnancy
Interventions: Not listed
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Knee Arthropathy
Interventions: Percutaneous peripheral nerve stimulation; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: CC-91633; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Boston, Massachusetts • St Louis, Missouri • Houston, Texas + 1 more

Conditions: Healthy Volunteer, Fatigue
Interventions: Niagen®Plus; Drug
Lead sponsor: ChromaDex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dehydration in Children, Dehydration
Interventions: LifeFlow; Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Month to 18 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV -1 Infection
Interventions: TMB-365, TMB-380, Baseline ART; Drug
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more

Conditions: Hypertriglyceridemia, Severe Hypertriglyceridemia
Interventions: ION775; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Lincoln, California • Aurora, Colorado • Boca Raton, Florida + 13 more

Conditions: Hearing Loss
Interventions: Signal-to-Noise Ratio Enhancement (SNR+), Signal-to-Noise Ratio Neutral (SNR-); Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Durham, North Carolina • Columbus, Ohio

Conditions: Cancer
Interventions: Offering Additional Resources to Promote Symptom Management; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: CPX-351; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acne
Interventions: TVB-3567, Placebo; Drug
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Sedentary Lifestyle
Interventions: Wellness control, Physical Activity Intervention; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 312 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Interventions: OCU-10-C-110 for Injection; Drug
Lead sponsor: Ocugenix Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Carmel, Indiana • Abilene, Texas • Willow Park, Texas

Conditions: Influenza, Human
Interventions: F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z, F2B22C/DL001Z, F2B22D/DL001Z, F2B22E/DL001Z, F2F22A/DL001Z, F2F22B/DL001Z, F2F22C/DL001Z, F2F22D/DL001Z, F2F22E/DL001Z, Control 1, F2F23D/DL001Z-NH, F2F23A/DL001Z-NH, F2F23B/DL001Z-NH, Control 2, F2F23C/DL001Z-NH, Control 3, F2F22F/DL001Z; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 24
States / cities: Hialeah, Florida • Miami, Florida • Chicago, Illinois + 21 more

Conditions: Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
Interventions: LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 6
States / cities: Los Angeles, California • New York, New York • Oklahoma City, Oklahoma + 2 more

Conditions: Chronic Pain Due to Cancer, Pain Catastrophizing
Interventions: Empowered Relief Course (Zoom); Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 120 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Mental Health Issue
Interventions: Expressive Helping, Caregiving Fact writing; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
Interventions: Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 53
States / cities: Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 44 more

Conditions: Type1 Diabetes Mellitus
Interventions: LY900014, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Atlanta, Georgia • Saint Louis Park, Minnesota

Conditions: Overweight, Obesity
Interventions: RIDE e-health application; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Type 1 Diabetes Mellitus
Interventions: Decision Support System, Usual Care; Device · Other
Lead sponsor: Daniel Chernavvsky, MD; Other
Eligibility: 21 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Evaluating the Use of Wearable Biosensors and PROs to Assess Performance Status in Patients With Cancer

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Study of the Validity of Using the MEQ to Measure Mindful Eating in Pregnant Women

Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Knee Surgery

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus

LifeFlow Fluid Study- Non- Critical Pediatric Patients Having a Trans Abdominal Ultrasound

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

A Study to Assess the Safety, Tolerability and Efficacy of ION775

The Hear Clear Study

Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

Seamos Saludables - Physical Activity Intervention Study for Latinas

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

A Study of LY3023414 in Participants With Advanced Cancer

Empowered Relief® for Cancer Survivors With Chronic Pain

Chinese American Family Caregiver Writing Study

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

A Study of LY900014 in a Medtronic Pump

Evaluation of the Remote Intervention for Diet and Exercise (RIDE)

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM